ClinicalTrials.gg
Not yet recruitingNCT07029139Updated Jun 19, 2025

A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy

A Phase 2 interventional study of JMT601 Injection and Rituximab in Primary Membranous Nephropathy, sponsored by Shanghai JMT-Bio Inc.. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-06-19.

Sponsored by Shanghai JMT-Bio Inc. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing rituximab in Glomerulonephritis, Membranous — 7 open to participants now, 8 under way, 4 of them phase 3. Rituximab · Glomerulonephritis, Membranous.

Planned enrollment
2nd of 15
156 · median 78
Started
2025
with 1 other
Phase 2
3 of 15
2 open now
Registered
14th of 15
by date
Lead sponsor
1 of 15
Shanghai JMT-Bio Inc.

Among the 15 studies testing rituximab in Glomerulonephritis, Membranous, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2025, is one of 3 in phase 2, and was the 14th registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

7 of the 15 studies testing rituximab in Glomerulonephritis, Membranous are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 14 (34%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing rituximab in Glomerulonephritis, Membranous, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, controlled, open-label, Phase Ⅱ clinical study to evaluate the efficacy, safety, Pharmacokinetics characteristics, Pharmacodynamics effects, and immunogenicity of JMT601 in participants with primary membranous nephropathy.

The study has two parts. Part one is dose escalation part, and Part two is dose expansion part.

03

Conditions studied

  • Primary Membranous Nephropathy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The age range is between 18 and 80 years old, regardless of gender.
  2. Diagnosed with primary membranous nephropathy by renal during the screening/induction period or within 24 months before screening. Pathological reports must be reviewed by the investigator prior to study drug administration.
  3. The (eGFR) estimated by CKD-EPI formula is ≥ 40ml/min/1.73m\^2, or the endogenous rate (CrCl) based on 24-hour urine examination is ≥ 40ml/min.
  4. Participants taking angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists must maintain a stable dose for at least 4 weeks before screening;
  5. Participants with systolic blood pressure ≤140 mmHg and diastolic blood pressure ≤ 90 mmHg at screening.
  6. During the screening period and the baseline visit, the 24-hour urine protein is > 3.5g.
  7. Have never received therapy for PMN (cyclophosphamide, calcineurin inhibitors, such as cyclosporine and tacrolimus) and B cell exhaustion therapy (such as rituximab); or after receiving the above treatment to achieve complete remission or partial remission (comprehensively judged and recorded by the researcher), and have not received the above treatment after recurrence (excluding those who are ineffective or resistant to B cell depletion drugs).
  8. Have fully understood this study and voluntarily signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Secondary membranous nephropathy.
  2. Diagnostic renal shows evidence of glomerular crescent formation, which suggests the diagnosis of other renal diseases or renal biopsy evidence of interstitial fibrosis/tubular atrophy in cortical area > 50%.
  3. Uncontrolled blood pressure as judged by the investigator within the 3 months prior to screening.
  4. Individuals with evidence of a ≥50% decrease in urine protein within the first 6 months before screening.
  5. Currently undergoing or planning to undergo renal replacement therapy during the study period.
  6. Type 1 diabetes or type 2 diabetes with diabetic nephropathy (confirmed by renal biopsy report) or without biopsy-confirmed diabetic nephropathy but with a diabetes duration ≥5 years.
  7. Presence of severe, progressive, or uncontrolled comorbidities.
  8. Individuals who have had or currently have malignant tumors.
  9. Participants with diseases requiring systemic therapy, or those judged by researchers to have autoimmune diseases that interfere with the clinical evaluation of primary membranous nephropathy or are not suitable for clinical trials.
  10. A history of previous or current hemolytic anemia, Evans syndrome, arteritis.
  11. Participants with suspected active or latent tuberculosis patients based on medical history or tuberculosis screening.
  12. Severe active bacterial, viral, fungal, mycobacterial, parasitic, or other infections requiring systemic antibiotics or antiviral treatment within 1 month before screening.
  13. Have received prescribed treatment for membranous nephropathy before screening.
  14. Participants using of complementary therapies that may interfere with the investigator's assessment of participant efficacy and safety within 4 weeks prior to randomization.
  15. or major surgery within 28 days before the drug administration or undergoing major surgery.
  16. Participants who have participated in clinical trials of other drugs with a screening time less than 30 days from the last administration or the five half-lives of the original drug (whichever is longer), or those who plan to participate in clinical trials of another drug during the study period.
  17. Participants who have received targeted 7 or signal regulatory protein α (SIRPα) therapy.
  18. A history of alcoholism or drug abuse within 12 months.
  19. Virology test results at screening meet the criteria:

    positivity; If HBsAg is negative and HBcAb is positive, HBV DNA should be exceeding the upper limit of the local laboratory reference range; Positive virus (HCV) antibody with detectable HCV RNA; Positive serology for (HIV).

  20. Any of the following abnormal laboratory test results during screening: \<80g/L, count\<100× 10\^9/L , \<1.5× 10\^9/L , or ALT values>2× (ULN), CD4+ T lymphocyte count \< 300 cells/μL, >450 ms for males and >460 ms for females.
  21. Participants who have previously shown resistance to CD20 inhibitors or cyclosporine.
  22. Known history of severe reactions to humanized monoclonal antibodies or documented allergy to any component of rituximab (dose-escalation part only), JMT601 injection, or cyclosporine (dose-expansion part only).
  23. Pregnant or lactating women; Women of not undergoing sterilization who are unwilling to use adequate during treatment and for at least 6 months after the last dose of the investigational drug.
  24. Men not undergoing sterilization who are unwilling to use barrier contraception during the study and for at least 6 months after the last dose of the investigational drug, and who refuse to ensure their partners use additional contraceptive methods (e.g., oral contraceptives, intrauterine devices, barrier methods, or spermicides).
  25. Other conditions that the investigator deems render the subject unsuitable for study participation.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    JMT601 (Part 1)

    JMT601

    Drug: JMT601 Injection

  • Active comparator
    Rituximab (Part 1)

    Rituximab

    Drug: JMT601 Injection · Drug: Cyclosporin Capsules

  • Experimental
    JMT601 (Part 2)

    JMT601

    Drug: Rituximab · Drug: Cyclosporin Capsules

  • Active comparator
    Cyclosporin Capsules (part 2)

    Cyclosporin Capsules

    Drug: JMT601 Injection · Drug: Rituximab

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events in Part 1

    Time frame: Up to 24 weeks

  2. Overall Remission Rate at week 52 in Part 2

    Participants with overall remission are those achieving either complete remission or partial remission

    Time frame: week 52

Secondary outcomes

  1. Blood drug concentration of JMT-601 in Part 1

    Time frame: week 24

  2. Immunological remission in the anti-PLA2R antibody positive population in Part 1

    Proportion of anti-PLA2R antibody-positive participants achieving immunological remission

    Time frame: week 12, 24

  3. Changes in anti-PLA2R antibody titers from baseline in anti-PLA2R antibody positive population in Part 1

    Time frame: week 24

  4. Overall Remission Rate in Part 1

    Time frame: weeks 12, 24

  5. Complete Remission Rate in Part 1

    A complete remission is defined as UPCR (based on 24-hour urine collection) ≤ 0.3, and a stable eGFR (remaining unchanged or decreasing by ≤ 15% compared with the baseline)

    Time frame: weeks 12, 24

  6. ADA (anti-drug antibody) positivity rate of JMT-601 in Part 1

    Time frame: week 24

  7. Nab (Neutralizing antibody) positivity rate of JMT-601 in Part 1

    Time frame: week 24

  8. Complete remission rate in Part 2

    Complete remission is defined as UPCR (based on 24-hour urine collection) ≤ 0.3, and a stable eGFR (remaining unchanged or decreasing by ≤ 15% compared with the baseline).

    Time frame: week 24, 52, 76, 104

  9. Overall remission rate in Part 2

    Participants with overall remission are those achieving either complete remission or partial remission. Partial remission is defined as a reduction of proteinuria to 0.3-3.5 g/24 h and 50% lower than baseline with stable renal function.

    Time frame: week 24, 52, 76, 104

  10. Relapse rate in Part 2

    A relapse is defined as reappearance of UPCR (based on 24-hour urine collection) \> 3.5 after complete or partial remission

    Time frame: week 52, 76, 104

  11. Time to first complete remission in Part 2

    Time frame: week 104

  12. Time to first overall remission in Part 2

    Time frame: week 104

  13. Time to first relapse in Part 2

    Time frame: week 104

  14. Change of urine protein from baseline in Part 2

    Time frame: week 12, 24, 52, 76, 104

  15. Change of estimated Glomerular Filtration Rate (eGFR) from baseline in Part 2

    Time frame: week 12, 24, 52, 76, 104

  16. Immunological response in the anti-PLA2R antibody positive population in Part 2

    Time frame: week 12, 24, 52, 76, 104

  17. Blood drug concentration of JMT-601 in Part 2

    Time frame: week 104

  18. ADA (anti-drug antibody) positivity rate of JMT-601 in Part 2

    Time frame: week 104

  19. Nab (Neutralizing antibody) positivity rate of JMT-601 in Part 2

    Time frame: week 104

  20. Adverse Events (AEs) in Part 2

    Time frame: week 104

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Apr 2027, 21 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Jun 19, 2025
StartEst.
Jun 30, 2025
Primary completionEst.
Apr 1, 2027
CompletionEst.
Mar 1, 2029
Last update
Jun 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07029139
Responsible party
Sponsor
First posted
Jun 19, 2025
Start date
Jun 30, 2025 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Jun 19, 2025

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CPO-107 · Rituximab · Cyclosporine

Start the discussion